News Release Details
The only comprehensive source for current medical benefit drug management approaches and data benchmarking
"As pioneers in the management of medical pharmacy spend, we are very
focused on providing a level of analysis that is unprecedented in the
industry," said
Among the key findings in the 2014 Medical Pharmacy Trend Report:
- Since 2010, medical pharmacy allowed amounts have experienced 9 to 13 percent year-over-year increases in the commercial population.
- Eighty one percent of payors reported that they did not vary member cost share requirements by site of service in 2014.
-
Oncology and oncology support medications represented 52 percent of
medical pharmacy spend for commercial members and nearly 60 percent
for
Medicare members. - Nearly 60 percent of payors representing 90 percent of covered lives reported that oncology practices in their service areas were being purchased by hospital systems.
- Forty nine percent of commercial expenditures were billed from hospital outpatient settings where drugs were typically reimbursed at two to three times the average sales price. This is an increase from 42 percent in 2010.
"We continue to see rising year-over-year trends in the medical pharmacy segment underscoring the critical importance of proven strategies and programs to help clients identify and manage this growing spend," said Kamal.
The fifth annual Medical Pharmacy Trend Report is available online at www.MagellanRxInsights.com. This report includes a combination of primary and secondary research methodologies to deliver a comprehensive view of payor perceptions and health plan actions related to medical benefit drugs which are commonly used to treat cancer, autoimmune disorders, immunodeficiencies and other complex diseases.
Kamal will be joined by
Magellan Rx Management provides a complete suite of industry-leading
pharmacy offerings, consisting of pharmacy benefit management,
About Magellan Health: Headquartered in Scottsdale, Ariz.,
Media Contact:
Laura
Schuntermann, 860-507-1822
lgschuntermann@magellanhealth.com
or
Investor
Contact:
rshapiro@magellanhealth.com
Source:
News Provided by Acquire Media